Medtronic Bounces Back During Quarter Four Of Financial Year 2021 As Procedure Volumes Normalize
Medtronic reported strong growth for the past quarter, with CEO Geoff Martha emphasizing the medtech giant’s efforts in M&A and R&D.
You may also be interested in...
Medtronic Announces FDA Approval Of SenSight Directional Lead System For Treating Movement Disorders
Medtronic said it will launch the SenSight DBS in the US after winning FDA approval. The total DBS market is expected to exceed $1bn by 2024, according to Meddevicetracker.
The company had issued two recalls in the past few months for the device due to recorded deaths and adverse events, but after further analyses has decided to pull it off the market altogether.
12 Deaths Prompt Another Class I Recall For Medtronic’s HeartWare – The Firm’s Fourth In Recent Weeks
The medtech giant has racked up yet another high-risk class I recall designation from the US FDA, this time for HeartWare Ventricular Assist Device (HVAD) cables and controller ports. It’s also the second class I recall action for the HeartWare device in a little more than six weeks, and the company’s fourth overall.